Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:1978500rdf:typepubmed:Citationlld:pubmed
pubmed-article:1978500lifeskim:mentionsumls-concept:C1979963lld:lifeskim
pubmed-article:1978500lifeskim:mentionsumls-concept:C0206012lld:lifeskim
pubmed-article:1978500lifeskim:mentionsumls-concept:C2003903lld:lifeskim
pubmed-article:1978500lifeskim:mentionsumls-concept:C0936012lld:lifeskim
pubmed-article:1978500lifeskim:mentionsumls-concept:C0205210lld:lifeskim
pubmed-article:1978500lifeskim:mentionsumls-concept:C0205195lld:lifeskim
pubmed-article:1978500pubmed:dateCreated1990-12-14lld:pubmed
pubmed-article:1978500pubmed:abstractTextNine double-blind studies comparing remoxipride to haloperidol in the treatment of acute schizophrenia formed the basis of this analysis. All studies followed a basic protocol with the main assessments performed regularly during the 4-6 week trial period according to the same methodology, thus allowing the data to be pooled. The results showed that remoxipride in a daily dose of 150-600 mg had a therapeutic effect comparable to that of haloperidol (5-45 mg/day), both on positive and negative symptoms. There was a clear advantage for remoxipride over haloperidol with regard to adverse events/symptoms, particularly extrapyramidal symptoms, but also drowsiness/somnolence and tiredness/fatigue. Anticholinergic drugs were used consistently less frequently as concomitant medication to alleviate extrapyramidal symptoms in the remoxipride group: the use of sedatives/hypnotics was approximately the same in both groups. Based on these and supportive clinical data, remoxipride seems to have a clinical profile characterized by antipsychotic efficacy in acute schizophrenia, apparently equal to that of haloperidol, and good tolerability in being non-sedative (in terms of drowsiness/somnolence) and with low incidences of extrapyramidal, autonomic, and endocrine symptoms.lld:pubmed
pubmed-article:1978500pubmed:languageenglld:pubmed
pubmed-article:1978500pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1978500pubmed:citationSubsetIMlld:pubmed
pubmed-article:1978500pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1978500pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1978500pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1978500pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1978500pubmed:statusMEDLINElld:pubmed
pubmed-article:1978500pubmed:issn0065-1591lld:pubmed
pubmed-article:1978500pubmed:authorpubmed-author:LewanderTTlld:pubmed
pubmed-article:1978500pubmed:authorpubmed-author:MorrisonDDlld:pubmed
pubmed-article:1978500pubmed:authorpubmed-author:WesterberghS...lld:pubmed
pubmed-article:1978500pubmed:issnTypePrintlld:pubmed
pubmed-article:1978500pubmed:volume358lld:pubmed
pubmed-article:1978500pubmed:ownerNLMlld:pubmed
pubmed-article:1978500pubmed:authorsCompleteYlld:pubmed
pubmed-article:1978500pubmed:pagination92-8lld:pubmed
pubmed-article:1978500pubmed:dateRevised2008-2-15lld:pubmed
pubmed-article:1978500pubmed:meshHeadingpubmed-meshheading:1978500-...lld:pubmed
pubmed-article:1978500pubmed:meshHeadingpubmed-meshheading:1978500-...lld:pubmed
pubmed-article:1978500pubmed:meshHeadingpubmed-meshheading:1978500-...lld:pubmed
pubmed-article:1978500pubmed:meshHeadingpubmed-meshheading:1978500-...lld:pubmed
pubmed-article:1978500pubmed:meshHeadingpubmed-meshheading:1978500-...lld:pubmed
pubmed-article:1978500pubmed:meshHeadingpubmed-meshheading:1978500-...lld:pubmed
pubmed-article:1978500pubmed:meshHeadingpubmed-meshheading:1978500-...lld:pubmed
pubmed-article:1978500pubmed:meshHeadingpubmed-meshheading:1978500-...lld:pubmed
pubmed-article:1978500pubmed:meshHeadingpubmed-meshheading:1978500-...lld:pubmed
pubmed-article:1978500pubmed:meshHeadingpubmed-meshheading:1978500-...lld:pubmed
pubmed-article:1978500pubmed:meshHeadingpubmed-meshheading:1978500-...lld:pubmed
pubmed-article:1978500pubmed:meshHeadingpubmed-meshheading:1978500-...lld:pubmed
pubmed-article:1978500pubmed:meshHeadingpubmed-meshheading:1978500-...lld:pubmed
pubmed-article:1978500pubmed:meshHeadingpubmed-meshheading:1978500-...lld:pubmed
pubmed-article:1978500pubmed:meshHeadingpubmed-meshheading:1978500-...lld:pubmed
pubmed-article:1978500pubmed:meshHeadingpubmed-meshheading:1978500-...lld:pubmed
pubmed-article:1978500pubmed:year1990lld:pubmed
pubmed-article:1978500pubmed:articleTitleClinical profile of remoxipride--a combined analysis of a comparative double-blind multicentre trial programme.lld:pubmed
pubmed-article:1978500pubmed:affiliationAstra Research Centre, Södertälje, Sweden.lld:pubmed
pubmed-article:1978500pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:1978500pubmed:publicationTypeClinical Triallld:pubmed
pubmed-article:1978500pubmed:publicationTypeComparative Studylld:pubmed
pubmed-article:1978500pubmed:publicationTypeRandomized Controlled Triallld:pubmed
pubmed-article:1978500pubmed:publicationTypeMulticenter Studylld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:1978500lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:1978500lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:1978500lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:1978500lld:pubmed